On May 17, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), to be held from June 2 – 6, 2017, at McCormick Place in Chicago, Illinois (Press release, TG Therapeutics, MAY 17, 2017, View Source [SID1234519202]). Abstracts are now available online and can be accessed at www.asco.org. Details of the data presentations are outlined below. Schedule your 30 min Free 1stOncology Demo! Oral Presentation:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
° Abstract Number: 7504
° Presentation Date & Time: Saturday, June 3, 2017 3:00 PM – 6:00 PM CT
° Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
° Presenter: Jeffrey P. Sharman, MD
Poster Discussion Presentation:
Title: Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL
° Abstract Number: 7511
° Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT (Poster Viewing); 1:15 PM-2:30 PM CT (Poster Discussion)
° Session Title: Poster Discussion Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
° Presenter: Loretta Nastoupil, MD
Trials in Progress Poster Presentation:
Title: KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
° Abstract Number: TPS7569
° Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT
° Session Title: Poster Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
° Presenter: Colleen Dorsey, BSN, RN
Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.